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Background: Cardiovascular disease is a frequent cause of death in peritoneal dialysis patients. Biocompatible
peritoneal dialysis solutions with neutral pH have been anticipated to reduce cardiovascular disease more than
conventional peritoneal dialysis solutions with low pH, but it remains unclear which factors at peritoneal dialysis
initiation increase cardiovascular risk in patients using biocompatible peritoneal dialysis solutions. This study was
undertaken to investigate which clinical factors at peritoneal dialysis initiation, including peritoneal transport status,
are associated with cardiovascular event in patients using biocompatible peritoneal dialysis solution.
Methods: This retrospective cohort study of peritoneal dialysis patients using biocompatible solutions with neutral
pH assessed relations of clinical parameters at peritoneal dialysis initiation to cardiovascular event during the
subsequent five years.
Results: Of 102 patients who started peritoneal dialysis, cardiovascular event occurred in 18. Age, history of
cardiovascular disease before peritoneal dialysis initiation, hemoglobin, serum albumin, C-reactive protein, peritoneal
permeability defined by the ratio of dialysate to plasma creatinine concentration at 4 hr (D/Pcre) in peritoneal
equilibration test (PET), number of patients in each PET category defined by D/Pcre, and peritoneal protein clearance
significantly differed between patients with and without cardiovascular event. For patients divided according to PET
category using Kaplan–Meier method, the group of high average to high peritoneal transporters exhibited significantly
high incidence of cardiovascular event and mortality compared with the groups of low and low-average peritoneal
transporters (Log rank; p = 0.0003 and 0.005, respectively). A Cox proportional hazards model showed independent
association of PET category classification with cardiovascular event.
Conclusions: Peritoneal permeability expressed as PET category at peritoneal dialysis initiation is an independent
cardiovascular risk factor in peritoneal dialysis patients using biocompatible peritoneal dialysis solution with neutral pH.
Greater peritoneal permeability at peritoneal dialysis initiation might reflect subclinical vascular disorders.
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Cardiovascular disease (CVD) is the most common
cause of death in end-stage renal disease (ESRD) pa-
tients. Cardiovascular mortality in ESRD patients is
about 10–20 times higher than among the general popu-
lation [1]. It is noteworthy that CVD causes not only
high mortality but also disabilities, which make it difficult
for patients to continue peritoneal dialysis (PD) therapy by
themselves. Physical disability caused by CVD affects the
selection of dialysis modality, which is one of the possible
reasons for the lack of increase of PD patients [2]. There-
fore, the management of CVD and its risk factors is a pri-
mary goal for PD patients [3]. Several non-traditional
cardiovascular risk factors specific for PD therapy are
known, such as decreased residual renal function, ultrafil-
tration failure, and peritoneal protein loss [3-5].
Although these findings were derived mainly from data
of patients using conventional PD solutions (CPDSs)
with low pH, biocompatible PD solutions (BPDSs) with
neutral pH have been widely used currently. Neverthe-
less, risk factors of CVD in PD patients using BPDSs re-
main unclear. This study investigated a patient cohort to
clarify the association of clinical parameters at PD initi-
ation, especially those specific for PD patients including
peritoneal transport status, with cardiovascular event oc-
currence in patients using BPDS.
Methods
Patients and data collection
This retrospective cohort study used data of PD patients
obtained from medical records at a single center: The
University of Tokyo Hospital. The Institutional ReviewTable 1 Patient characteristics at PD initiation (N = 102, mean
Age (years) 60.6 ± 13.9
Male gender (n [%]) 78 [77%]





Diabetes mellitus (n [%]) 35 [34%]
CVD before PD initiation (n [%]) 25 [25%]
Automated PD (n [%]) 91 [89%]
Body mass index (kg/m2) 22.1 ± 3.4
Systolic blood pressure (mmHg) 131 ± 18
Diastolic blood pressure (mmHg) 77 ± 12
Urine volume (ml/day) 1182 ± 612
UF volume (ml/day) 446 ± 658
Hemoglobin (g/dl) 10.7 ± 1.6
ESRD, end stage renal disease; CVD, cardiovascular disease; UF, ultrafiltration; D/Pcr
of the 4 h dwell period in peritoneal equilibration test; PET, peritoneal equilibrationBoard of The University of Tokyo approved the study.
Because this study retrospectively collected the data
available from the medical records, the Institutional
Review Board of The University of Tokyo waives the re-
quirement to obtain documentation of the consent.
In actuality, 137 adult patients started PD therapy dur-
ing 2001–2009. After excluding patients who had received
maintenance hemodialysis or kidney transplantation be-
fore PD initiation and those who had been followed up for
less than 6 months after PD initiation, 102 patients were
analyzed in this study. All patients underwent PD using
glucose-based BPDS with neutral pH and devices provided
by Terumo Corp. (Tokyo, Japan). Within 6 months after
PD initiation, peritoneal membrane function by peritoneal
equilibration test (PET), urinary and peritoneal solute
clearance, and peritoneal protein excretion were evaluated
in all patients. In PET, 2.5% glucose concentration 2-L vol-
ume PD solution was used. The ratio of creatinine con-
centration in dialysate to plasma at the completion of the
4 h dwell period (D/Pcre) was evaluated to estimate low-
molecular-weight solute transport [6]. All the patients
were classified into PET categories by the value of D/Pcre
[6]. Then they were divided into three groups: low (L)
transporters (D/Pcre <0.50), low-average (LA) transporters
(0.50 ≤D/Pcre <0.65), and high-average to high (HA + H)
transporters (D/Pcre ≥0.65). The body weight and blood
pressure were measured on the same day of PET. Patient
data at PD initiation were collected, including age, gender,
cause of ESRD, and CVD history before PD initiation.
Laboratory data were measured at the time of PET.
Residual renal function and dialysis dosage were calcu-
lated as the weekly Kt/V from the 24 h urinary and± SD)
Serum albumin (g/dl) 3.5 ± 0.5
Blood urea nitrogen (mg/dl) 52.1 ± 14.7
Serum creatinine (mg/dl) 6.6 ± 2.5
Serum corrected calcium (mg/dl) 8.9 ± 1.1
Serum phosphate (mg/dl) 4.6 ± 1.1
C-reactive protein (mg/dl) 0.43 ± 0.68
Total cholesterol (mg/dl) 198 ± 39
Triglyceride (mg/dl) 173 ± 129
Renal weekly Kt/V 1.14 ± 0.62
Total weekly Kt/V 2.23 ± 0.58




HA + H 24 [24%]
P-PrCl (ml/day) 58.9 ± 26.9
e, the ratio of creatinine concentration in dialysate to plasma at the completion
test; P-PrCl, peritoneal protein clearance.
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urine and dialysate. To evaluate peritoneal protein excre-
tion, peritoneal protein clearance (P-PrCl) was calculated
as described previously [5,7]. Occurrence of cardiovas-
cular event (CV event) after PD initiation was exam-
ined based on medical records and was evaluated as a
primary outcome. CV event was defined for this study
as follows: coronary artery disease which needs to
be treated by angioplasty or coronary artery bypass,Table 2 Comparison between patient groups with or





(−) N = 84 (+) N = 18
Age (years) 59.1 ± 14.3 67.4 ± 9.7 < 0.01
Male gender 75% 83% 0.45





Diabetes mellitus 31% 50% 0.13
CVD before PD initiation 20% 44% 0.03
Automated PD 88% 94% 0.43
Body mass index (kg/m2) 22.1 ± 3.4 21.7 ± 3.3 0.73
Systolic blood pressure (mmHg) 130 ± 18 140 ± 18 0.07
Diastolic blood pressure (mmHg) 77 ± 12 75 ± 12 0.24
Urine volume (ml/day) 1166 ± 579 1258 ± 763 0.57
UF volume (ml/day) 477 ± 640 286 ± 745 0.31
Hemoglobin (g/dl) 10.8 ± 1.7 10.2 ± 1.1 0.03
Serum albumin (g/dl) 3.6 ± 0.5 3.3 ± 0.5 0.01
Blood urea nitrogen (mg/dl) 52.5 ± 14.1 50.1 ± 17.2 0.49
Serum creatinine (mg/dl) 7.0 ± 2.6 5.7 ± 2.3 0.08
Serum corrected calcium (mg/dl) 8.9 ± 1.2 9.0 ± 0.7 0.90
Serum phosphate (mg/dl) 4.7 ± 1.1 4.3 ± 1.3 0.10
C-reactive protein (mg/dl) 0.39 ± 0.65 0.63 ± 0.83 0.05
Total cholesterol (mg/dl) 198 ± 40 201 ± 38 0.87
Triglyceride (mg/dl) 175 ± 138 164 ± 74 0.49
Renal weekly Kt/V 1.16 ± 0.65 1.12 ± 0.52 0.99
Total weekly Kt/V 2.23 ± 0.60 2.19 ± 0.50 0.88
D/Pcre 0.58 ± 0.12 0.65 ± 0.11 < 0.01
PET category < 0.01
L 23% 0%
LA 60% 50%
HA + H 18% 50%
P-PrCl (ml/day) 54.7 ± 24.2 72.7 ± 34.1 0.03cerebrovascular disease such as transient ischemic at-
tack and stroke, and peripheral artery disease that re-
quires surgical revascularization or amputation, which
occurred within five years after PD initiation. Tech-
nique survival within five years after PD initiation and
death from PD initiation to the first 1 year after PD
cessation were also examined.
Statistical analysis
Continuous and categorical data were expressed respect-
ively as means ± SD and proportions. Data were comparedTable 3 Comparison between patient groups with or
without death after PD initiation
Variables Death (mean ± SD) p value
(−) N = 87 (+) N = 15
Age (years) 58.0 ± 12.8 75.3 ± 11.0 < 0.01
Male gender 78% 67% 0.33





Diabetes mellitus 34% 40% 0.62
CVD before PD initiation 24% 27% 0.85
Automated PD 91% 80% 0.22
Body mass index (kg/m2) 22.2 ± 3.3 21.3 ± 3.8 0.36
Systolic blood pressure (mmHg) 130 ± 17 134 ± 24 0.48
Diastolic blood pressure (mmHg) 78 ± 11 67 ± 14 < 0.01
Urine volume (ml/day) 1222 ± 619 948 ± 530 0.11
UF volume (ml/day) 484 ± 649 249 ± 693 0.21
Hemoglobin (g/dl) 10.8 ± 1.7 10.2 ± 1.2 0.04
Serum albumin (g/dl) 3.6 ± 0.4 3.1 ± 0.5 < 0.01
Blood urea nitrogen (mg/dl) 53.0 ± 14.4 46.6 ± 15.4 0.11
Serum creatinine (mg/dl) 6.9 ± 2.5 4.5 ± 1.9 < 0.01
Serum corrected calcium (mg/dl) 8.9 ± 1.2 9.1 ± 0.7 0.55
Serum phosphate (mg/dl) 4.8 ± 1.1 3.9 ± 0.8 < 0.01
C-reactive protein (mg/dl) 0.40 ± 0.69 0.61 ± 0.60 < 0.01
Total cholesterol (mg/dl) 199 ± 39 193 ± 41 0.58
Triglyceride (mg/dl) 178 ± 136 147 ± 73 0.86
Renal weekly Kt/V 1.13 ± 0.63 1.23 ± 0.58 0.57
Total weekly Kt/V 2.21 ± 0.56 2.30 ± 0.73 0.61
D/Pcre 0.58 ± 0.11 0.67 ± 0.15 0.03
PET category < 0.01
L 21% 7%
LA 61% 40%
HA + H 18% 53%
P-PrCl (ml/day) 56.3 ± 27.9 67.5 ± 17.3 0.02
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Cochran-Armitage test. Incidence of CV event, mortal-
ity, and technique survival rate were examined by com-
paring patients divided into PET categories using the
Kaplan–Meier method and the log-rank test. Predictors of
CV event were identified using the Cox proportional haz-
ards model with variables that were significantly different
between groups with and without CV event with a p value
of less than or equal to 0.01. A p value of less than 0.05 was
inferred as statistically significant.
Statistical analyses were conducted using software
(JMP 9.0; SAS Institute Inc., Cary, NC).
Results
Patient data and characteristics
Table 1 presents patient data and characteristics at PD
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Figure 1 Kaplan–Meier plots of incidence of CV event (A), survival rat
with neutral pH according to PET category. 102 patients were divided i
with D/Pcre <0.50 are in the low (L) group (n = 19), 0.50 ≤ D/Pcre <0.65 are
high average and high (HA + H) group (n = 24).based PD solutions with neutral pH (MIDPERIQ L® 135
or MIDPERIQ L® 250; Terumo Corp.). For this study,
patients were classified into groups: 19 (19%) into the
L group, 59 (58%) into the LA group, and 24 (24%)
into the HA + H group (HA group, n = 18; H group,
n = 6) (Table 1). Of the 102 patients, 91 (89%) were
treated continuously by automated PD (APD) from
immediately after PD initiation to cessation of PD. In
these patients, APD instead of continuous ambulatory
PD (CAPD) was selected according to patient prefer-
ences. Laboratory data collection was performed more
than 1 month after PD catheter insertion to avoid the
influence of surgery. The recommended period to per-
form first PET after PD initiation is within 3 months
[8]. In this study, the mean (± standard deviation) dur-
ation from PD initiation to laboratory data collection
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nto three groups based on PET category defined by D/Pcre. Patients
in the low average (LA) group (n = 59), and D/Pcre ≥0.65 are in the
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A CV event occurred in 18 patients (17.6%) within five
years after PD initiation. Table 2 presents variables for
which a significant difference was found between groups
with and without a CV event. Age, prevalence of CVD
before PD initiation, C-reactive protein, D/Pcre, and
P-PrCl were significantly higher, and hemoglobin and
serum albumin were significantly lower in the group of
patients with CV event than in the group of patients
without CV event (Table 2). Distributions of patients
classified into each PET category differed significantly
between groups with and without CV event (Table 2).
Of 102 patients, 15 patients (15%) were confirmed to
have died between PD initiation and 1 year after PD ces-












CVD before PD initiation 16%
Automated PD 90%
Body mass index (kg/m2) 20.9 ± 2.8
Systolic blood pressure (mmHg) 126 ± 14
Diastolic blood pressure (mmHg) 75 ± 12
Urine volume (ml/day) 1155 ± 401
UF volume (ml/day) 654 ± 440
Hemoglobin (g/dl) 11.2 ± 1.2
Serum albumin (g/dl) 3.8 ± 0.4
Blood urea nitrogen (mg/dl) 50.8 ± 15.8
Serum creatinine (mg/dl) 6.5 ± 2.0
Serum corrected calcium (mg/dl) 9.1 ± 0.8
Serum phosphate (mg/dl) 4.7 ± 1.4
C-reactive protein (mg/dl) 0.38 ± 0.83
Total cholesterol (mg/dl) 197 ± 27
Triglyceride (mg/dl) 227 ± 215
Renal weekly Kt/V 1.26 ± 0.56
Total weekly Kt/V 2.21 ± 0.53
D/Pcre 0.45 ± 0.05
P-PrCl (ml/day) 44.2 ± 23.4
*p <0.05 vs. L group; **p <0.05 vs. LA group.category differed significantly between the groups with
and without death (Table 3).Impact of PET category classification at PD initiation on
the prognosis of PD patients
The incidence of CV event, survival rate, and technique
survival rate were examined by comparing patients in
the L, LA, and HA + H groups using the Kaplan–Meier
method and the log-rank test (Figure 1). Patients in the
HA + H group had worse CVD morbidity, survival rate,
and technique survival rate than those in the L or LA
group. Patients in the HA + H group had significantly
lower levels of serum albumin and higher P-PrCl than
those in the L or LA group (Table 4).T category defined by D/Pcre
category (mean ± SD) p value
LA HA + H
N = 59 N = 24










22.6 ± 3.5 21.8 ± 3.5 0.18
132 ± 18 134 ± 22 0.31
78 ± 11 75 ± 15 0.54
1260 ± 684 1012 ± 543 0.49
437 ± 616 300 ± 868 0.24
10.6 ± 1.9 10.6 ± 1.2 0.28
3.6 ± 0.4 3.3 ± 0.5*,** < 0.01
54.2 ± 13.8 47.9 ± 15.3 0.26
6.9 ± 2.6 5.9 ± 2.7 0.28
8.8 ± 1.3 9.0 ± 0.7 0.66
4.9 ± 1.0 4.1 ± 1.0** < 0.01
0.41 ± 0.62 0.54 ± 0.73 0.09
195 ± 44 207 ± 37 0.35
161 ± 105 160 ± 69 0.39
1.14 ± 0.60 1.09 ± 0.74 0.58
2.20 ± 0.54 2.32 ± 0.73 0.95
0.57 ± 0.05* 0.75 ± 0.10*,** < 0.01
56.0 ± 24.9 74.1 ± 27.8*,** < 0.01
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event in five years after PD initiation are shown (Table 5).
Regarding forward stepwise multivariate analysis, the
PET category remained as an independent predictor of
CV event (Table 5). When analysis using the Cox pro-
portional hazards model was conducted using variables that
were significantly different between the patient groups with
and without CV event with p value of less than or equal to
0.05, the PET category was determined as an independent
predictor of CV event (Table 5).
Discussion
This study demonstrated that peritoneal small solute
permeability, expressed as PET category classification
defined by D/Pcre, was independently associated with a
CV event within five years after PD initiation in patients
using BPDS. This report is the first describing evaluation
of the relation between clinical parameters at PD initi-
ation and prognosis in patients using BPDS with neutral
pH, although many previous clinical studies evaluated
this relation in patients using CPDSs and icodextrin with
low pH.
Our results showed that PET category at PD initiation
is an independent risk factor of CVD in PD patients
using BPDF with neutral pH. Similar relations between
peritoneal permeability and prognosis shown by our
study have been demonstrated in previous studies in
patients using CPDSs with low pH [9-11]. Because PD
solutions have adverse effects on both the local periton-
eal and systemic effects induced by glucose degradation
products coupled with other factors such as low pH,
BPDSs had been anticipated for use to improve the
prognosis of PD patients [12]. However, a recent system-
atic review was unable to demonstrate significant effects
of BPDSs on survival and technique failure [13]. ResultsTable 5 Univariate and multivariate Cox regression model on
Unadju
Variable Hazard ratio [95% C
Model 1 Age 1.03 [0.99–1.06]
PET category 3.70 [1.62–8.43]
Model 2 Age 1.01 [0.98-.1.05]
Serum albumin 0.29 [0.08-1.02]
PET category 3.21 [1.37-7.52]
Model 3 Age 1.03 [0.99–1.08]
CVD before PD initiation 1.82 [0.58–5.69]
Hemoglobin 0.91 [0.66–1.26]
Serum albumin 0.40 [0.09–1.83]
C-reactive protein 1.19 [0.55–2.61]
PET category 4.65 [1.78–12.16]
P-PrCl 0.99 [0.97–1.01]obtained from the present study support the view that
the type of PD solution does not have a significant effect
on the PD patient prognosis. Although the effects of
BPDSs on prognosis remain unclear, some benefits have
been reported. For instance, BPDSs have benefits of re-
ducing peritoneal membrane injury, which might be fa-
vorable for the preservation of peritoneal ultrafiltration
capacity and which might decrease the risk of CVD
caused by fluid overload [14]. Reportedly, BPDSs can
preserve residual renal function and levels of markers of
endothelial dysfunction [13,15-17]. Because local and
systemic effects of BPDSs are preferred to those of
CPDSs, the fluid overload state, which plays a pivotal
role in CVD progression, is expected to be improved by
BPDSs [3,12]. The impact of BPDSs and clinical factors
affecting the prognosis of patients using BPDSs should
be investigated further.
Some possible explanations about the linkage be-
tween peritoneal permeability and prognosis of PD
patients have been considered. High peritoneal perme-
ability, which causes rapid equilibration of glucose
across the peritoneal membrane, engenders ultrafiltra-
tion failure. A continuous fluid overload state acceler-
ates left ventricular hypertrophy and increases serum
concentrations of natriuretic peptides, which are
markers of CVD and all-cause mortality in PD patients
[3]. High peritoneal transport increases CVD morbid-
ity and mortality by accelerating hypoalbuminemia, a
well-known prognostic marker in PD patients, through
increased peritoneal protein loss [9,10]. Increased
peritoneal permeability is probably associated with
high mortality in patients with malnutrition–inflam-
mation–atherosclerosis (MIA) syndrome through peri-
toneal protein loss and hypoalbuminemia [18]. High
transport status of the peritoneum might be a markercardiovascular event within five years after PD initiation
sted Adjusted
I] p value Hazard ratio [95% CI] p value
0.09 1.03 [0.99–1.06] 0.09
< 0.01 3.70 [1.62–8.43] < 0.01
0.40 – –
0.05 0.24 [0.08-0.77] 0.02
< 0.01 3.49 [1.49-8.15] < 0.01
0.13 1.03 [0.99–1.07] 0.11
0.31 – –
0.57 – –
0.24 0.31 [0.09–1.11] 0.07
0.65 – –
< 0.01 4.25 [1.79–10.10] < 0.01
0.54 – –
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erosclerotic comorbidity after PD initiation [19].
Several studies have revealed that high peritoneal per-
meability is not an independent risk factor of death and
technique failure. In addition, high transporter treated
by APD had superior survival and technique survival
[20-22]. Actually, APD tends to be selected for patients
with increased peritoneal permeability because short ex-
change of PD solution by automated cycler can increase
ultrafiltration via reduction of glucose absorption [22].
In our study, almost all patients were treated by APD
from immediately after PD initiation to cessation of PD
whether their peritoneal permeability was increased or
not. Therefore, the PET category at PD initiation might
predict the prognoses of patients treated by APD.
Although classification into ‘Slow’ (D/Pcre <0.55–
0.60), ‘Average’, and ‘Fast’ (D/Pcre >0.80) transporter sta-
tus was recently recommended for prescription manage-
ment in clinical practice [23], classification into the four
PET categories (L, LA, HA, and H) has been used in
many studies, as it was for this study. We divided the
patients into the three categories of L, LA, and HA + H
in this study. However one previous study, in which the
HA group comprised most of the patients, showed no
difference of CV event rate among the PET category
groups of L + LA, HA, and H [22]. When the patients in
this study were divided into L + LA, HA, and H groups,
or Slow, Average, and Fast groups, the Kaplan–Meier
method and the log-rank test showed that the patients
in the L + LA group or the Slow group of this study had
a significantly high CV event free rate, patient survival
rate, and technique survival rate (Additional file 1: Figures
S1 and S2). Therefore, the association of peritoneal
transport status with prognosis of PD patients using
BPDS was apparently similar, irrespective of the pa-
tient categorization based on the PET results.
Our study has some limitations. This study was a
retrospective cohort study of patients from a single cen-
ter and the number of patients was not large. A large
prospective study including patients using BPDS from
multiple centers should be conducted. Because only
glucose-based BPDS was used and because APD was
mainly performed in this study, it remains unclear
whether all the results from our study are applicable to
patients using other PD solutions or treated by CAPD.
Conclusions
Peritoneal permeability expressed as PET category de-
fined by D/Pcre at PD initiation is an independent car-
diovascular risk factor in patients using BPDS. Increased
peritoneal permeability at PD initiation might contribute
to the progress of atherosclerosis in PD patients by
several mechanisms such as fluid overload and MIA
syndrome. Findings from this study can contribute tomanagement of PD patients using BPDS by enabling
identification of patients with high risk of CVD and by
enabling early intervention to improve their prognosis
from immediately after PD initiation.
Additional file
Additional file 1: Kaplan–Meier plots of incidence of CV event
(Figures S1A and S2A), survival rate (Figures S1B and S2B), and
technique survival rate (Figures S1C and S2C) of PD patients
according to PET category. 102 patients were divided into three
groups based on PET category defined by D/Pcre. Patients with D/Pcre
<0.65 are in the low and low-average (L + LA) group (n = 78), 0.65 ≤ D/
Pcre ≤0.80 are in the high-average (HA) group (n = 18), and D/Pcre >0.80
are in the high (H) group (n = 6) (Figure S1). Patients with D/Pcre <0.57
are in the Slow group (n = 48), 0.57 ≤ D/Pcre ≤0.80 are in the Average
group (n = 48), and D/Pcre >0.80 are in the Fast group (n = 6) (Figure S2).
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